Chinese Medical E-ournals Database

Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition) ›› 2019, Vol. 15 ›› Issue (04): 357 -362. doi: 10.3877/cma.j.issn.1673-5250.2019.04.001

Special Issue:

Editorials

Current research status on biomarkers of " new" bronchopulmonary dysplasia

Dan Zhou1, Fang Shi1, Hanmin Liu1,()   

  1. 1. Department of Respiration, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
  • Received:2019-01-10 Revised:2019-04-30 Published:2019-08-01
  • Corresponding author: Hanmin Liu
  • About author:
    Corresponding author: Liu Hanmin, Email:
  • Supported by:
    National Natural Science Foundation of China(81601326)

Bronchopulmonary dysplasia (BPD) is a serious pulmonary complication that affects the survival rate and quality of premature infants. Early diagnosis of BPD is critical to improve the survival rate and prevent chronic lung remodeling of premature infants. So finding appropriate biomarkers for early diagnosis of BPD has always been the focuses of this field. But the recent studies of BPD biomarkers are mostly focused on the perspective of lung inflammation and infection, lung fibrosis and oxidative stress, which are the pathological physiological characteristics of typical BPD, rarely in terms of pulmonary alveoli development block and pulmonary microcirculation disturbance of lung, which are typical characteristics of pathological physiological of " new" BPD. Recent studies have shown that there may be some relationship between " new" BPD and pulmonary alveoli related biomarkers of Krebs Von den lungen-6 (KL-6) and Clara cell secretory protein (CC16), and pulmonary microvascular related biomarkers of vascular endothelial growth factor (VEGF), angiopoietin (Ang) and endostatin (ES), which may probably be the appropriate biomarkers to predict the development of " new" BPD. In addition, the omics related biomarkers of BPD have received more and more attentions in recent years. So, in this article, the authors will review the recent research advances of biomarkers of " new" BPD in terms of pulmonary alveoli development, pulmonary micro-angiogenesis and omics, which may contribute to early prevention and treatment of BPD and improve prognosis and life quality of these premature infants.

[1]
Strueby L, Thébaud B. Advances in bronchopulmonary dysplasia[J]. Expert Rev Respir Med, 2014, 8(3): 327-338.
[2]
Brener Dik PH, Niño Gualdron YM, Galletti MF, et al. Bronchopulmonary dysplasia: incidence and risk factors[J]. Arch Argent Pediatr, 2017, 115(5): 476-482.
[3]
Kiciński P, Ksiak M, Nowiczewski M, et al. Bronchopulmonary dysplasia in very and extremely low birth weight infants - analysis of selected risk factors[J]. Pol Merkur Lekarski, 2017, 42(248): 71-75.
[4]
Voynow JA. " New" bronchopulmonary dysplasia and chronic lung disease[J]. Paediatr Respir Rev, 2017, 24(1): 17-18.
[5]
Lal CV, Ambalavanan N. Biomarkers, early diagnosis, and clinical predictors of bronchopulmonary dysplasia[J]. Clin Perinatol, 2015, 42(4): 739-754.
[6]
Rivera L, Siddaiah R, Oji-Mmuo C, et al. Biomarkers for bronchopulmonary dysplasia in the preterm infant[J]. Front Pediatr, 2016, 4: 33.
[7]
Lal CV, Ambalavanan N. Cellular and humoral biomarkers of bronchopulmonary dysplasia[J]. Early Hum Dev, 2017, 105: 35-39.
[8]
Miura T. Models of lung branching morphogenesis[J]. J Biochem, 2015, 157(3): 121-127.
[9]
Hadchouel A, Franco-Montoya ML, Delacourt C. Altered lung development in bronchopulmonary dysplasia[J]. Birth Defects Res Part A Clin Mol Teratol, 2014, 100(3): 158-167.
[10]
Jensen EA, Schmidt B. Epidemiology of bronchopulmonary dysplasia[J]. Birth Defects Res Part A Clin Mol Teratol, 2014, 100(3): 145-157.
[11]
Jobe AH. Mechanisms of lung injury and bronchopulmonary dysplasia[J]. Am J Perinatol, 2016, 33(11): 1076-1078.
[12]
Silva DM, Nardiello C, Pozarska A, et al. Recent advances in the mechanisms of lung alveolarization and the pathogenesis of bronchopulmonary dysplasia[J]. Am J Physiol Lung Cell Mol Physiol, 2015, 309(11): L1239-L1272.
[13]
Niedermaier S, Hilgendorff A. Bronchopulmonary dysplasia: an overview about pathophysiologic concepts [J]. Mol Cell Pediatr, 2015, 2(1): 2.
[14]
Matsumura H, Ichiba H, Ohnishi S, et al. Histologic chorioamnionitis, amniotic fluid interleukin 6, krebs von den lungen 6, and transforming growth factor beta1 for the development of neonatal bronchopulmonary dysplasia[J]. Jpn Clin Med, 2017, 8: 1179066017696076.
[15]
Wang KY, Huang XM, Lu H, et al. A comparison of KL-6 and clara cell protein as markers for predicting bronchopulmonary dysplasia in preterm infants[J]. Dis Markers, 2014, 2014: 736536.
[16]
Dilli D, Özyazici A, Dursun A, et al. Predictive values of plasma KL-6 in bronchopulmonary dysplasia in preterm infants[J]. Turk J Med Sci, 2017, 47(2): 621-626.
[17]
McAuley DF, Matthay MA. Clara cell protein CC16. A new lung epithelial biomarker for acute lung injury[J]. Chest, 2009, 135(6): 1408-1410.
[18]
Guzmán-Bárcenas J, Calderón-Moore A, Baptista-González H, et al. Clara cell protein expression in mechanically ventilated term and preterm infants with respiratory distress syndrome and at risk of bronchopulmonary dysplasia: a pilot study[J]. Can Respir J, 2017, 2017: 8074678.
[19]
Hendrix AY, Kheradmand F. The role of matrix metalloproteinases in development, repair, and destruction of the lungs[J]. Prog Mol Biol Transl Sci, 2017, 148: 1-29.
[20]
Tian XY, Zhang XD, Li QL, et al. Biological markers in cord blood for prediction of bronchopulmonary dysplasia in premature infants[J].Clin Exp Obstet Gynecol, 2014, 41(3): 313-318.
[21]
Lee C, An J, Kim JH, et al. Low levels of tissue inhibitor of metalloproteinase-2 at birth may be associated with subsequent development of bronchopulmonary dysplasia in preterm infants[J]. Korean J Pediatr, 2015, 58(11): 415.
[22]
Alvira CM. Aberrant pulmonary vascular growth and remodeling in bronchopulmonary dysplasia[J]. Front Med (Lausanne), 2016, 3: 21-35.
[23]
Berry MJ. The heart of the matter: a vascular hypothesis for bronchopulmonary dysplasia[J]. J Physiol (Lond), 2019, 597(4): 991-992.
[24]
Ma XN, Li QP, Feng ZC. Research progress in cytokines and signaling pathways for promoting pulmonary angiogenesis and vascular development[J]. Chin J Contemp Pediatr, 2013, 15(9): 800-805.
[25]
Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signalling in the cardiovascular and lymphatic systems[J]. Clin Sci, 2017, 131(1): 87-103.
[26]
Fagiani E, Christofori G. Angiopoietins in angiogenesis[J]. Cancer Lett, 2013, 328(1): 18-26.
[27]
Biel NM, Siemann DW. Targeting the angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference[J]. Cancer Lett, 2016, 380(2): 525-533.
[28]
Procianoy RS, Hentges CR, Silveira RC. Vascular endothelial growth factor/placental growth factor heterodimer levels in preterm infants with bronchopulmonary dysplasia[J]. Am J Perinatol, 2016, 33(5): 480-485.
[29]
Kim DH, Kim HS. Serial changes of serum endostatin and angiopoietin-1 levels in preterm infants with severe bronchopulmonary dysplasia and subsequent pulmonary artery hypertension[J]. Neonatology, 2014, 106(1): 55-61.
[30]
Mohamed WA, Niyazy WH, Mahfouz AA. Angiopoietin-1 and endostatin levels in cord plasma predict the development of bronchopulmonary dysplasia in preterm infants[J]. J Trop Pediatr, 2011, 57(5): 385-388.
[31]
El Shemi MS, Tawfik S, Khafagy SM, et al. Endothelin 1 as a predictor marker for bronchopulmonary dysplasia in preterm neonates with respiratory distress syndrome[J]. J Neonatal Perinatal Med, 2017, 10(1): 79-83.
[32]
Piersigilli F, Bhandari V. Biomarkers in neonatology: the new " omics" of bronchopulmonary dysplasia[J]. J Matern Fetal Neonatal Med, 2016, 29(11): 1758-1764.
[33]
Lal CV, Ambalavanan N. Genetic predisposition to bronchopulmonary dysplasia[J]. Semin Perinatol, 2015, 39(8): 584-591.
[34]
Yang Y, Qiu J, Kan Q, et al. MicroRNA expression profiling studies on bronchopulmonary dysplasia: a systematic review and Meta-analysis[J]. Genet Mol Res, 2013, 12(4): 5195-5206.
[35]
Lohmann P, Luna RA, Hollister EB, et al. The airway microbiome of intubated premature infants: characteristics and changes that predict the development of bronchopulmonary dysplasia[J]. Pediatr Res, 2014, 76(3):294-301.
[1] Zhidong Zhao, Zhongli Li. Research progress of early diagnosis and treatment in osteoarthritis[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(05): 689-693.
[2] Lu Wang, Yang Fan. Advances in endometrial cancer-related biomarker research[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(05): 511-516.
[3] Zhengyun Hu, Jianwei Shi, Jianwei Shen, Bing Wang, Chunmiao Jiang, Chong Liu. Identification of hub genes associated with bronchopulmonary dysplasia in preterm infants based on machine learning[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 446-454.
[4] Xu Wei, Ge Zhang, Jinlin Wu. Monitoring and treatment of neonatal sepsis-induced coagulopathy[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(04): 379-386.
[5] Lili Lou, Hanmin Liu. Current research status of susceptibility genes and epigenetics on childhood asthma[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(03): 249-255.
[6] Ping Yang, Shimin Xu, Liangliang Li, Xiangyun Yin, Hongmin Xi, Lili Ma, Xianghong Li. Influencing factors of bronchopulmonary dysplasia complicated with metabolic bone disease in preterm infants[J]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2023, 19(02): 202-211.
[7] Zhiming Li, Chenming Guo, Xiaochen Zhuang, Xueqin Hou, Junxi Gao. Comparative study of qualitative and quantitative indicators of contrast-enhanced ultrasound in early breast cancer[J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 639-643.
[8] Ruiqi Gu, Hongsheng Fang, Guoxiang Cai. Application and progress of circulating tumor DNA detection technology in the diagnosis and treatment of colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(06): 453-459.
[9] Xinyu Shi, Jinbing Sun, Songbing He. Progress of blood biomarkers in neoadjuvant chemoradiotherapy of rectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(03): 228-233.
[10] Chengren Zhang, Yaochun Lv, Xiongfei Yang, Binbin Du. Research progress on influencing factors and diagnostic biomarkers of anastomotic leakage in postoperative rectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(02): 152-157.
[11] Shan Wang, Qing Ma, Lan Yao, Huayu Yang. Correlation between folic acid therapy and serum level of miR-150-5p in elderly patients undergoing maintenance hemodialysis[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2023, 12(03): 139-144.
[12] Xiang Yang, Lanqi Guo, Jianfeng Xie, Haibo Qiu. Role of metagenomics next-generation sequencing in the pathogen diagnosis in sepsis[J]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2023, 09(03): 292-297.
[13] Rongju Wu, Pingchao Xiang. Correlation between frequent exacerbation phenotype of chronic obstructive pulmonary disease and inflammatory markers[J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(9): 939-947.
[14] Fangfang Guo, Minmin Li. Research progress on non-invasive biomarkers of lupus nephritis[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(04): 271-275.
[15] Fanhui Yan, Mingli Zhao, Ying Li, Fangming Guo, Jingdong Zhan, Yingjie Zhao, Yang Wang, Yanfen Zhang, Xiaomei Zhao. Study on the correlation between the degree of coronary vascular lesion and serum levels of TNF-α and VEGF in patients with acute coronary syndrome[J]. Chinese Journal of Diagnostics(Electronic Edition), 2023, 11(03): 158-164.
Viewed
Full text


Abstract